IRCT20200915048726N3招募中2 期
Comparing the efficacy of the bismuth-based quadruple therapy containing a high dose of metronidazole with a concomitant regimen containing clarithromycin for eradicating Helicobacter pylori infection
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Patients have H. pylori eradication indication based on endoscopic evidence
- •Patients with positive Rapid urease test
- •Patients with positive histology of H. pylori infection
排除标准
- •Age under 18 years
- •Reluctance to participate in the study
- •Pregnancy and lactation
- •Patients taking concomitant anticoagulants, corticosteroids or ketoconazole.
- •Patients with a history of gastric surgery
- •Patients with a history of heart failure, lung disease, chronic kidney failure, liver disease (cirrhosis or chronic hepatitis for any reason), or a history of cancer
- •Consumption of alcohol in any amount
- •The presence of any type of malignancy
- •History of drug allergy to the drugs in this study
- •History of H. pylori eradication regimens at any time before this study
研究者
相似试验
已完成
4 期
Cure rate and side effects comparison between the sequential bismuth based quadruple therapy and the concomitant bismuth based quadruple therapy in treating patients carrying antibiotic resistant Helicobacter pylori strain.Helicobacter pylori unable to be eradicated with standard triple therapies.Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonInfection - Studies of infection and infectious agentsACTRN12615000493549niversity of Western Australia200
已完成
不适用
Comparison of 10 days nonbismuth-containing quadruple therapy and modified sequential therapy for Helicobacter pylori eradication (Hybrid study): Randomised controlled trialDiseases of the digestive systemKCT0000728Kyungpook National University Medical Center480
招募中
4 期
Comparison of bismuth quadruple therapy with Clarithromycin quadruple therapy in the treatment of Helicobacter pyloriPACTR202304550587833Galpharma200
已完成
不适用
Comparison of non-bismuth concomitant and standard triple therapies as a first-line treatment option for Helicobacter pylori in JapaHelicobacter pylori infectionJPRN-UMIN000018164Tokai University School of Medicine220
已完成
4 期
BIAsp-3858Diabetes Mellitus Type II.Non-insulin-dependent diabetes mellitus type IIIRCT201104266297N1ovo Nordisk A/S300